

# MARKET REPORT



## Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

## Summary

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

## Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

#### Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note\*: Some sections may be missing if data is unavailable for the company.

## Additional Details

**Publisher** : Global Data  
**Reference** : GDPH1255D  
**Number of Pages** : 157  
**Report Format** : PDF  
**Publisher Information** :

**GlobalData»**

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

- Table of Contents Table of Contents 3List of Tables 6List of Figures 7Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 18Asset Purchase 18Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US\$56.5 Million 20Abbott Labs Acquires AP214 From Action Pharma For US\$110 Million 22Venture Financing 23NeuroGenetic Pharma Raises US\$0.2 Million In Venture Financing 23NeuroGenetic Pharma Secures Investment In Venture Financing 24Private Equity 25Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25Partnerships 27BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27Cipher Pharma and Italmex Enter into Distribution Agreement 28Veropharm Enters into Agreement with Bion 29Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31ALK-Abello Expands Partnership with Abbott Labs 32Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34Abbott Molecular Enters into Co-Development Agreement with Biocartis 35Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38biOasis Technologies Enters Into Research Agreement With Abbott Labs 39Abbott India Enters Into Joint Venture Agreement With Syngene International 40Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43Licensing Agreements 44Abbott Molecular Enters into Licensing Agreement with Institut Curie 44Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45Sepstone Enters into Licensing Agreement with Abbott Labs 47Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49Abbott India Enters into Licensing Agreement with Bharat Biotech 50Equity Offering 51Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51Abbott Sells stock of Mylan for USD2.29 Billion 52AbbVie Spin Out from Abbott Laboratories 53Debt Offering 54Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71Alere Completes Private Placement Of Notes Due 2020 For US\$425 Million 72Alere Completes Private Placement Of Notes Due 2018 For US\$450 Million 73CFR International Completes Public Offering Of Notes For US\$300 Million 74Abbott Completes Private Placement Of Notes Due 2015 For US\$500 Million 75Abbott Completes Private Placement Of Notes Due 2042 For US\$2.6 Billion 76Abbott Completes Private Placement Of Notes Due 2015 For US\$3.5 Billion 77Abbott Completes Private Placement Of Notes Due 2017 For US\$4 Billion 79Abbott Completes Private Placement Of Notes Due 2018 For US\$1 Billion 80Abbott Completes Private Placement Of Notes Due 2022 For US\$3.1 Billion 81Asset Transactions 82Corona Remedies Acquires Obimet and Thyrocab from Abbott 82Abbott India May Sell Low-End Brands 83Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84Abbott Labs Rumored To Divest Part Of Generic Drug Business 86Acquisition 87Abbott Labs Acquires Alere 87Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90Optum

Acquires Alere Health for USD600 Million 91Persivia Acquires Alere Analytics 92Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For US\$86.3 Million 97Arriva Medical Acquires Simplex Healthcare 99GardenHills To Acquire 47.99% Stake In Verofarm 100Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103CFR Pharma Acquires Laboratorio Franco Colombiano Lafranco And Its Subsidiaries 105AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107CFR Pharma Acquires 50% Stake In Stelligence For US\$21 Million 109STARLIMS Technologies Acquires Distribution Partners 110CFR Pharma Acquires 41.88% Stake In Domesco Medical For US\$14.4 Million 111Abbott Laboratories - Key Competitors 112Abbott Laboratories - Key Employees 113Abbott Laboratories - Locations And Subsidiaries 115Head Office 115Other Locations & Subsidiaries 115Recent Developments 133Financial Announcements 133Jul 18, 2018: Abbott reports second-Quarter 2018 Results 133Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 136Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 139Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 142Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 145Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 147Corporate Communications 149Sep 22, 2017: Abbott and the Abbott Fund Provide \$2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 149Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With \$1 Million to Help Families Affected by Hurricane Irma 150Aug 29, 2017: Abbott and the Abbott Fund Donate \$1 Million to Support Hurricane Harvey Relief Efforts 151Government and Public Interest 152Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 152Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 154Product News 155Apr 18, 2018: Abbott to produce new infertility drug in Russia 155Other Significant Developments 156Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 156Appendix 157Methodology 157About GlobalData 157Contact Us 157Disclaimer 157

# List Of Tables in Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

## List of Tables

Abbott Laboratories, Pharmaceuticals & Healthcare, Key Facts, 2017	2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018	8
Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018	9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018	10
Abbott Laboratories, Deals By Therapy Area, 2012 to YTD 2018	11
Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018	13
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018	14
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson	18
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US\$56.5 Million	20
Abbott Labs Acquires AP214 From Action Pharma For US\$110 Million	22
NeuroGenetic Pharma Raises US\$0.2 Million In Venture Financing	23
NeuroGenetic Pharma Secures Investment In Venture Financing	24
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion	25
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs	27
Cipher Pharma and Italmex Enter into Distribution Agreement	28
Veropharm Enters into Agreement with Bion	29
Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement	30
AstraZeneca Enters into Co-Development Agreement with Abbott Labs	31
ALK-Abello Expands Partnership with Abbott Labs	32
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software	33
Abbott Labs Enters into Co-Development Agreement with US Department of Defense	34
Abbott Molecular Enters into Co-Development Agreement with Biocartis	35
Abbott Enters Into Distribution Agreement With WhanIn For Depakote	36
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial	37
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs	38
biOasis Technologies Enters Into Research Agreement With Abbott Labs	39



Abbott India Enters Into Joint Venture Agreement With Syngene International 40

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43

Abbott Molecular Enters into Licensing Agreement with Institut Curie 44

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45

Sepstone Enters into Licensing Agreement with Abbott Labs 47

Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48

Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49

Abbott India Enters into Licensing Agreement with Bharat Biotech 50

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51

Abbott Sells stock of Mylan for USD2.29 Billion 52

AbbVie Spin Out from Abbott Laboratories 53

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71

Alere Completes Private Placement Of Notes Due 2020 For US\$425 Million 72

Alere Completes Private Placement Of Notes Due 2018 For US\$450 Million 73

CFR International Completes Public Offering Of Notes For US\$300 Million 74

Abbott Completes Private Placement Of Notes Due 2015 For US\$500 Million 75

Abbott Completes Private Placement Of Notes Due 2042 For US\$2.6 Billion 76

Abbott Completes Private Placement Of Notes Due 2015 For US\$3.5 Billion 77

Abbott Completes Private Placement Of Notes Due 2017 For US\$4 Billion 79

Abbott Completes Private Placement Of Notes Due 2018 For US\$1 Billion 80

Abbott Completes Private Placement Of Notes Due 2022 For US\$3.1 Billion 81

Corona Remedies Acquires Obimet and Thyrocab from Abbott 82

Abbott India May Sell Low-End Brands 83

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84

Abbott Labs Rumored To Divest Part Of Generic Drug Business 86

Abbott Labs Acquires Alere 87

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90

Optum Acquires Alere Health for USD600 Million 91

Persivia Acquires Alere Analytics 92

Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93

Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96

GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For US\$86.3 Million 97

Arriva Medical Acquires Simplex Healthcare 99

GardenHills To Acquire 47.99% Stake In Verofarm 100

Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103

CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105

AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106

Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107

CFR Pharma Acquires 50% Stake In Stelligence For US\$21 Million 109

STARLIMS Technologies Acquires Distribution Partners 110

CFR Pharma Acquires 41.88% Stake In Domesco Medical For US\$14.4 Million 111

Abbott Laboratories, Key Competitors 112

Abbott Laboratories, Key Employees 113

Abbott Laboratories, Other Locations 115

Abbott Laboratories, Subsidiaries 115

# List Of Figures, Charts and Diagrams in Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-1-2018]

## List of Figures

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13

# How to Buy...

Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 12-10-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/224464>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$250** | Single User Price
- \$500** | Site License Price
- \$750** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.